Clinical Trial Update: BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial in China is comparing BCMA CAR-T therapy to autologous stem cell transplant in transplant-eligible patients with multiple myeloma, currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Abecma (idecabtagene vicleucel)
• Carvykti (ciltacabtagene autoleucel)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING